Mobile

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with Rad...

Update Il y a 4 ans
Reference: EUCTR2015-003932-11

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with Radiographic Axial Spondyloarthritis

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Compare both ixekizumab regimens (80 mg every 2 weeks or 80 mg every 4 weeks vs placebo in patients with active radiographic axial spondyloarthritis at week 16.

Inclusion criteria

  • Radiographic Axial Spondyloarthritis

Links